Soluble CX3CL1 has been associated with better prognosis in colorectal cancer (54), has demonstrated antitumor effects in murine lung (55) and hepatocellular cancer models (56) and was identified as a predictor for response to immune checkpoint blockade in patients with non-small-cell-lung cancer (57). Here, CX3CL1 is linked to colorectal cancer.